The Corby facility was nominated in several categories, including “Best Process Factory” and “Overall Best UK Factory.”
The awards evaluation highlighted Catalent’s ability to quickly introduce new customer products from the site. This was recently demonstrated by a packaging launch involving GlaxoSmithKline’s anti-viral product Relenza®, which has been recommended by a number of global health authorities for treatment of H1N1 influenza. The Corby team moved from preliminary discussion through design, implementation, validation, and into full production in just twelve weeks, helping GlaxoSmithKline meet increasing demand for the product.




















